The deal-hungry French big pharma gives Translate’s mRNA vaccine technology a massive boost.
The German government will not get exclusive access to Curevac’s Covid-19 vaccine as part of its 23% stake purchase, the company insists.
Followers of Nordic Nanovector and Oxford Biomedica, among others, will pay close attention to an early focus of yesterday’s deal.
Abbvie pays handsomely to join the CD20 bispecific brawl, handing over $750m to Genmab for access to a project that trails the competition.
Five reasons why Astra should buy Gilead, and five why a move of this sort is pure fantasy.
Arcus insists that its new partnership is a good deal, but shareholders make their feelings known.
Merck & Co might have got off to a slow start, but now hopes to make up for lost time with multiple projects.
Speculation that Sanofi is gearing up for acquisitions could grow after it banks billions from its Regeneron stake sale.
The UK big pharma group unveils funding and a clinical programme that could overshadow the efforts of its biotech rival.